Hong Kong
· Delayed Price · Currency is HKD Ascletis Pharma Statistics
Total Valuation
Ascletis Pharma has a market cap or net worth of HKD 6.04 billion. The enterprise value is 3.97 billion.
| Market Cap | 6.04B |
| Enterprise Value | 3.97B |
Important Dates
The next estimated earnings date is Friday, May 30, 2025.
| Earnings Date | May 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Ascletis Pharma has 961.81 million shares outstanding. The number of shares has decreased by -6.75% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 961.81M |
| Shares Change (YoY) | -6.75% |
| Shares Change (QoQ) | -2.92% |
| Owned by Insiders (%) | 64.69% |
| Owned by Institutions (%) | 0.96% |
| Float | 129.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4,423.96 |
| PB Ratio | 2.89 |
| P/TBV Ratio | 2.90 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.40 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.88, with a Debt / Equity ratio of 0.00.
| Current Ratio | 12.88 |
| Quick Ratio | 12.82 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,658.33 |
Financial Efficiency
Return on equity (ROE) is -13.97% and return on invested capital (ROIC) is -11.70%.
| Return on Equity (ROE) | -13.97% |
| Return on Assets (ROA) | -10.96% |
| Return on Invested Capital (ROIC) | -11.70% |
| Return on Capital Employed (ROCE) | -20.52% |
| Revenue Per Employee | 5,911 |
| Profits Per Employee | -1.39M |
| Employee Count | 231 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.10 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +379.39% in the last 52 weeks. The beta is 0.36, so Ascletis Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.36 |
| 52-Week Price Change | +379.39% |
| 50-Day Moving Average | 6.63 |
| 200-Day Moving Average | 3.00 |
| Relative Strength Index (RSI) | 49.85 |
| Average Volume (20 Days) | 8,956,859 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ascletis Pharma had revenue of HKD 1.37 million and -320.25 million in losses. Loss per share was -0.32.
| Revenue | 1.37M |
| Gross Profit | 782,167 |
| Operating Income | -430.60M |
| Pretax Income | -320.25M |
| Net Income | -320.25M |
| EBITDA | -415.65M |
| EBIT | -430.60M |
| Loss Per Share | -0.32 |
Balance Sheet
The company has 2.08 billion in cash and 8.12 million in debt, giving a net cash position of 2.07 billion or 2.15 per share.
| Cash & Cash Equivalents | 2.08B |
| Total Debt | 8.12M |
| Net Cash | 2.07B |
| Net Cash Per Share | 2.15 |
| Equity (Book Value) | 2.09B |
| Book Value Per Share | 2.15 |
| Working Capital | 1.93B |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 57.29% |
| Operating Margin | -31,538.04% |
| Pretax Margin | -23,455.65% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Ascletis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 6.75% |
| Shareholder Yield | 6.75% |
| Earnings Yield | -5.30% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |